Pursuant to the provisions of article 228 of the Consolidated Text of the Securities Market Act, approved by the Legislative Royal Decree 4/2015, of 23 October, Grifols, S.A. ("Grifols") hereby informs about the following

RELEVANT EVENT

The U.S. Food and Drug Administration ("FDA") has approved Grifols' new 20% subcutaneous immunoglobulin product, Xembify®, which is used to treat primary immunodeficiencies.

The FDA approval of Xembify® marks the culmination of an important R+D+i project for Grifols, as well as a step forward in its long-term sustainable growth strategy, and it reinforces Grifols' commitment to patients and healthcare professionals by expanding its product portfolio to better serve individuals with primary immunodeficiencies. Grifols is currently a market leader in the production and marketing of immunoglobuline, with 30.3%¹ market share (in volume) in the United States.

The company plans to launch Xembify® in the United States during the last quarter of 2019, and it is working with healthcare authorities to obtain approval in Canada, Europe, and other markets.

In Barcelona, on 4 July 2019

Nuria Martín Barnés
Secretary to the Board of Directors

¹ Source: Grifols Global Plasma Database, provisional data 2018